Literature DB >> 22914834

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

Avner Thaler1, Anat Mirelman, Tanya Gurevich, Ely Simon, Avi Orr-Urtreger, Karen Marder, Susan Bressman, Nir Giladi.   

Abstract

OBJECTIVE: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene.
METHODS: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale.
RESULTS: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007).
CONCLUSION: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914834      PMCID: PMC3430708          DOI: 10.1212/WNL.0b013e3182684646

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Toward a redefinition of Parkinson's disease.

Authors:  Matthew B Stern; Anthony Lang; Werner Poewe
Journal:  Mov Disord       Date:  2012-01       Impact factor: 10.338

2.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

4.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

5.  Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients.

Authors:  Kathy Dujardin; Luc Defebvre; Alain Duhamel; Pascal Lecouffe; Pascal Rogelet; Marc Steinling; Alain Destée
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

6.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Authors:  Jennifer Kachergus; Ignacio F Mata; Mary Hulihan; Julie P Taylor; Sarah Lincoln; Jan Aasly; J Mark Gibson; Owen A Ross; Timothy Lynch; Joseph Wiley; Haydeh Payami; John Nutt; Demetrius M Maraganore; Krzysztof Czyzewski; Maria Styczynska; Zbigniew K Wszolek; Matthew J Farrer; Mathias Toft
Journal:  Am J Hum Genet       Date:  2005-02-22       Impact factor: 11.025

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study.

Authors:  Carmen Cristea Janvin; Dag Aarsland; Jan Petter Larsen
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-09       Impact factor: 2.680

9.  Dissociation between spontaneous and reactive flexibility in early Parkinson's disease.

Authors:  Rachel Tomer; Tali Fisher; Nir Giladi; Judith Aharon-Peretz
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  2002-06

10.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

Authors:  Dag Aarsland; Kjeld Andersen; Jan P Larsen; Anette Lolk; Per Kragh-Sørensen
Journal:  Arch Neurol       Date:  2003-03
View more
  27 in total

1.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

3.  Heterozygous deletion of the LRFN2 gene is associated with working memory deficits.

Authors:  Julien Thevenon; Céline Souchay; Gail K Seabold; Inna Dygai-Cochet; Patrick Callier; Sébastien Gay; Lucie Corbin; Laurence Duplomb; Christel Thauvin-Robinet; Alice Masurel-Paulet; Salima El Chehadeh; Magali Avila; Delphine Minot; Eric Guedj; Sophie Chancenotte; Marlène Bonnet; Daphne Lehalle; Ya-Xian Wang; Paul Kuentz; Frédéric Huet; Anne-Laure Mosca-Boidron; Nathalie Marle; Ronald S Petralia; Laurence Faivre
Journal:  Eur J Hum Genet       Date:  2015-10-21       Impact factor: 4.246

Review 4.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 5.  The spectrum of cognitive impairment in Lewy body diseases.

Authors:  Jennifer G Goldman; Caroline Williams-Gray; Roger A Barker; John E Duda; James E Galvin
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Heather L Melrose; Thomas Mosley; Jun Ming Wang
Journal:  Neurobiol Learn Mem       Date:  2017-05-06       Impact factor: 2.877

7.  Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.

Authors:  Yael Jacob; Keren Rosenberg-Katz; Tanya Gurevich; Rick C Helmich; Bastiaan R Bloem; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman; Talma Hendler; Avner Thaler
Journal:  Hum Brain Mapp       Date:  2019-02-21       Impact factor: 5.038

8.  Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.

Authors:  Anat Mirelman; Roy N Alcalay; Rachel Saunders-Pullman; Kira Yasinovsky; Avner Thaler; Tanya Gurevich; Helen Mejia-Santana; Deborah Raymond; Mali Gana-Weisz; Anat Bar-Shira; Laurie Ozelius; Lorraine Clark; Avi Orr-Urtreger; Susan Bressman; Karen Marder; Nir Giladi
Journal:  Mov Disord       Date:  2015-03-21       Impact factor: 10.338

9.  Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.

Authors:  Rick C Helmich; Avner Thaler; Bart F L van Nuenen; Tanya Gurevich; Anat Mirelman; Karen S Marder; Susan Bressman; Avi Orr-Urtreger; Nir Giladi; Bastiaan R Bloem; Ivan Toni
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

Review 10.  Initial cognitive changes in Parkinson's disease.

Authors:  Daniel Weintraub; Alexander I Tröster; Connie Marras; Glenn Stebbins
Journal:  Mov Disord       Date:  2018-03-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.